Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer
Clinical trial NCT04239001 · UNKNOWN
Trial details
- NCT number
- NCT04239001
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- Status
- UNKNOWN
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-01
- Primary completion
- 2020-12-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.